Molecular Dynamics Simulations of Viral Envelope Proteins: Insights into Host Receptor Binding and Drug Resistance

Introduction

Molecular dynamics (MD) simulations have become an indispensable tool in computational virology for investigating the structural and dynamic properties of viral envelope proteins. These proteins, which include hemagglutinin (HA) in influenza viruses, spike (S) glycoproteins in coronaviruses, and fusion (F) or glycoprotein (G) complexes in paramyxoviruses and rhabdoviruses, mediate the critical steps of host receptor recognition and membrane fusion [1, 2]. Understanding their conformational behavior at atomic resolution is essential for deciphering host tropism, immune evasion, and the molecular basis of drug resistance [3, 4]. In veterinary medicine, such insights inform the design of vaccines and antivirals for pathogens of livestock, poultry, companion animals, and wildlife [5, 6].

MD simulations complement experimental structural biology (e.g., cryo-EM, X-ray crystallography) by providing a time-resolved view of protein motions, from local side-chain fluctuations to large-scale domain rearrangements [7, 8]. They allow the calculation of free energy landscapes, identification of cryptic binding pockets, and assessment of mutation-induced allosteric effects that may alter receptor affinity or antibody neutralization [9, 10]. This review examines the theoretical foundations of MD simulations as applied to viral envelope proteins, surveys key findings across viral families relevant to veterinary virology, and discusses implications for understanding drug resistance mechanisms.

Computational Methods in Viral Envelope Protein Simulations

MD simulations rely on classical force fields (e.g., CHARMM, AMBER, OPLS, GROMOS) to model the interatomic interactions of proteins, lipids, and water [11]. For envelope proteins, accurate representation of the lipid bilayer environment is critical, as many glycoproteins are membrane-anchored and undergo pH- or receptor-dependent conformational transitions [12, 2]. Simulations of soluble ectodomains are often performed using explicit solvent models (e.g., TIP3P, SPC/E) with periodic boundary conditions and particle mesh Ewald electrostatics [13, 14]. Typical simulation timescales range from nanoseconds to microseconds for conventional MD, although enhanced sampling techniques such as replica exchange, metadynamics, and Markov state models (MSMs) can access slower conformational changes [7, 15].

The choice of force field and simulation protocol must account for post-translational modifications, particularly N- and O-linked glycans, which play a major role in shielding epitopes and modulating receptor interactions [8, 16, 17]. Glycan parameters are often taken from the GLYCAM force field or CHARMM carbohydrate force fields [18]. Solvation free energies and binding affinities are frequently calculated using end-point methods such as MM/PBSA or MM/GBSA, or more rigorous free energy perturbation (FEP) [14, 9]. The following table summarizes common computational components used in viral glycoprotein MD studies.

Applications to Influenza Hemagglutinin

Influenza A viruses, including those circulating in avian and swine populations, rely on hemagglutinin (HA) for receptor binding and membrane fusion. MD simulations have been instrumental in characterizing the conformational dynamics of HA and the effects of antigenic drift mutations [4]. The convergent evolution of mutations such as N156K in A(H1N1)pdm09 HA was shown to contribute to antigenic cluster transitions, with MD studies revealing altered loop dynamics in the receptor binding domain [4]. Simulations of avian HA variants have helped correlate glycan binding specificity (α2,3 vs α2,6 sialic acids) with host tropism, a key factor for pandemic risk assessment [19, 4]. Additionally, MD has been used to investigate the M2 proton channel and its resistance to adamantane drugs, although M2 is not an envelope glycoprotein per se; however, the principles of resistance mutation analysis apply broadly [19].

Coronaviruses: Spike Protein Dynamics and Receptor Interactions

Coronaviruses such as SARS-CoV-2 (zoonotic), MERS-CoV (camelid origin), and canine coronavirus (CCoV) have been extensively studied using MD simulations of their spike (S) proteins [20, 21, 7, 5]. The prefusion state of S exists in a metastable conformation that transitions to a postfusion state upon receptor engagement and proteolytic cleavage. The D614G mutation, which arose early in the SARS-CoV-2 pandemic, was shown by Kearns et al. using MD to reshape allosteric networks and opening mechanisms, increasing accessibility of the receptor binding domain (RBD) [7]. Other mutations, such as N481K, have been characterized structurally and functionally to alter RBD dynamics and immune recognition [20]. Intra-host recombination in SARS-CoV-2 can produce epistatic spike interactions that influence temperature-dependent adaptation [21].

Glycan shielding is a critical factor in immune evasion; MD simulations have revealed how N-glycans on the SARS-CoV-2 spike modulate tilting and exposure of epitopes, analogous to mechanisms observed in HIV-1 Env [8, 17]. The Omicron variant epitope reorganization linked to sotrovimab resistance was elucidated through MD and glycan analysis [17]. Allosteric effects induced by RBD mutations have been mapped using energy landscape analysis and mutational profiling [9]. Furthermore, MD simulations combined with virtual screening have identified small molecules and natural compounds that disrupt the spike-ACE2 interface, including cannabidiol and cinnamic acid derivatives [14, 22]. In a veterinary context, a heptad repeat 2 (HR2)-derived peptide inhibitor for canine coronavirus was designed and characterized using MD, providing a basis for fusion inhibitor development [5].

Flavivirus and Togavirus Envelope Proteins

Dengue virus (DENV) and Zika virus (ZIKV) are mosquito-borne flaviviruses that can infect nonhuman primates and other mammals. MD simulations of the DENV envelope (E) protein have been used to identify inhibitors targeting the prefusion E protein, using a consensus AI-based and physics-based virtual screening approach [23]. Variations in the E protein of ZIKV, including potential O-glycosylation sites, have been modeled to assess impacts on viral stability and receptor binding [24]. Tick-borne encephalitis virus (TBEV) E protein has been studied for molecular mimicry that may trigger autoimmunity, with MD providing conformational insight into epitope exposure [3].

Retrovirus Envelope Glycoproteins: HIV-1 and FIV

HIV-1 Env (gp120-gp41) remains a paradigmatic system for MD studies of viral envelope dynamics. The conformational variability of the Env trimer and its vulnerability to broadly neutralizing antibodies have been mapped using long-timescale simulations [1]. N-glycans on HIV-1 Env modulate its tilting relative to the membrane, affecting accessibility of conserved epitopes [8]. The HIV-1 envelope protein, when embedded in a lipid bilayer, exhibits distinct dynamics that can be captured with coarse-grained and all-atom MD [2]. Compounds such as allophycocyanin have been shown through MD and experimental assays to inhibit HIV-1 gp120 and reverse transcriptase via enthalpy-driven binding [25]. These findings are relevant to veterinary lentiviruses such as FIV, for which envelope glycoprotein dynamics remain understudied but conceptually analogous.

Rhabdovirus and Filovirus Glycoproteins

Rabies virus (RABV) glycoprotein G mediates receptor binding (neurotropism) and pH-dependent fusion. While fewer MD studies have been published on RABV G, the principles derived from other class III fusion proteins can be applied. Ebola virus (EBOV) glycoprotein (GP) has been targeted by QSAR-guided and fragment-based drug design using MD to evaluate monoterpenoid inhibitors that bind the GP1-GP2 interface [26]. These approaches can be extended to veterinary filoviruses such as Lloviu virus or other rhabdoviruses.

Envelope Protein Assembly and Viroporin Interactions

MD simulations have also been applied to viral envelope assembly. The SARS-CoV-2 envelope (E) protein, a small viroporin, has been studied for its synergistic protein-protein and protein-lipid interactions that drive assembly with the M protein [11]. Clustering of M and E proteins in lipid bilayers influences virion morphogenesis [12]. In white spot syndrome virus (WSSV), a crustacean pathogen, multi-target inhibitors against envelope proteins VP28, VP26, and VP24 have been investigated using MD and virtual screening, demonstrating the applicability of these methods in aquaculture virology [6].

Identifying Drug Resistance Mechanisms Through MD

Drug resistance mutations often arise in envelope proteins under selective pressure from antivirals or host immune responses. MD simulations can elucidate the structural basis of resistance by comparing free energy landscapes of wild-type and mutant proteins in the presence or absence of inhibitors. For SARS-CoV-2, resistance to monoclonal antibodies like sotrovimab was linked to glycan shielding and epitope reorganization, with MD capturing the altered dynamics of the RBD [17]. In HIV-1, resistance to entry inhibitors such as maraviroc (targeting CCR5) involves mutations in gp120 that alter coreceptor binding preferences; MD studies have mapped these conformational changes [1, 25]. For influenza, mutations in HA that reduce binding to neutralizing antibodies are frequently located at antigenic sites and can be predicted by analyzing the flexibility and solvent accessibility of the HA surface [4, 19].

Cryptic pocket identification is a powerful application of MD. By simulating protein dynamics in the absence of ligand, transient pockets may appear that are not evident in static crystal structures. These pockets can then be targeted by small molecule inhibitors. This strategy has been successfully applied to the SARS-CoV-2 spike RBD and the influenza HA stem region [27, 28]. Allostery also plays a key role in drug resistance; the D614G mutation in spike was shown to allosterically stabilize the open conformation of the RBD, enhancing ACE2 binding and in some cases affecting inhibitor efficacy [7].

Conclusion and Future Perspectives

MD simulations of viral envelope proteins have provided profound insights into the atomic-level dynamics that govern host receptor binding and drug resistance. By integrating enhanced sampling techniques, accurate force fields, and experimental validation, computational virologists can predict the effects of mutations, identify cryptic pockets, and guide the rational design of vaccines and antivirals for both human and animal pathogens. Veterinary applications, including canine coronavirus fusion inhibitors, WSSV envelope protein blockers, and influenza HA host range determinants, underscore the translational potential of these methods [5, 6, 4]. Future directions include the use of machine learning to accelerate free energy calculations, the development of more realistic membrane models, and the application of coarse-grained MD to entire viral particles [12, 7]. The workflow below illustrates a typical computational pipeline for studying receptor binding and drug resistance in viral envelope proteins.

graph TD
    A[Experimental Structure / Homology Model], > B[System Setup: Protein, Glycans, Lipid Bilayer, Solvent, Ions]
    B, > C[Energy Minimization and Equilibration]
    C, > D[Production MD Simulation (Conventional or Enhanced Sampling)]
    D, > E{Analysis}
    E, > F[Conformational Dynamics (RMSD, PCA, FEL)]
    E, > G[Binding Free Energy Calculations (MM/PBSA, FEP)]
    E, > H[Mutation Effects: Allostery, Stability, Resistance]
    E, > I[Cryptic Pocket Detection (fpocket, MDpocket)]
    F, > J[Receptor Binding Mechanism]
    G, > J
    H, > K[Drug Resistance Prediction]
    I, > L[Virtual Screening for Novel Inhibitors]
    L, > M[In Vitro / In Vivo Validation]

The continued maturation of MD methodology, combined with advances in structural biology and artificial intelligence, promises to further unravel the complex dynamics of viral envelope proteins and accelerate the development of countermeasures against emerging zoonotic and veterinary pathogens.

References

[1] Cao Y, Im W. Conformational variability of HIV-1 Env trimer and viral vulnerability. Elife. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42360802/

[2] Majumder A, Dutta M, Cherek L et al. Structure and Dynamics of the HIV-1 Envelope Protein on the Virion Envelope. bioRxiv. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42239368/

[3] Timofeeva AM, Aulova KS, Ulyanova YS et al. Molecular Mimicry by the Tick-Borne Encephalitis Virus E Protein: A Hidden Link to Autoimmunity. Int J Mol Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42278275/

[4] Tian Y, Jiang D, Ma W et al. Convergent evolution of the N156K mutation in A(H1N1)pdm09 hemagglutinin contributes to antigenic drift and cluster transition. Emerg Microbes Infect. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42267384/

[5] Iovane V, Giugliano R, Gentile A et al. Design and Characterization of an HRC-Derived Peptide Inhibitor of Canine Coronavirus Spike-Mediated Fusion. Pathogens. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41901768/

[6] Hossen Z, Sajjad Hossain M, Naim Uddin Forhad M et al. Multi-target inhibitors of white spot syndrome virus envelope proteins (VP28, VP26, and VP24) to protect shrimp (Penaeus monodon): An integrated virtual screening, pharmacokinetic, and molecular dynamics study. Microb Pathog. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42055173/

[7] Kearns FL, Bogetti AT, Calvó-Tusell C et al. D614G reshapes allosteric networks and opening mechanisms of SARS-CoV-2 spikes. Proc Natl Acad Sci U S A. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42101997/

[8] Shehata M, Casalino L, Duquette M et al. N-Glycans modulate tilting of HIV-1 envelope glycoprotein. Nat Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41986331/

[9] Alshahrani M, Gatlin W, Ludwick M et al. Mechanisms of Binding and Immune Escape Resistance for Broadly Neutralizing Antibodies Targeting Distinct Conserved SARS-CoV-2 Spike Epitopes: A Hierarchical Approach Integrating Mutational Profiling and Energy Landscape Analysis. Int J Mol Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42123600/

[10] Soliman OA, Shahine Y, Baecker D et al. Beyond the Mutation Abyss: Revisiting SARS-CoV-2 Receptor-Binding Domain Evolution from ACE2 Binding Optimization to Immune Epitope Remodeling. Pathogens. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41901725/

[11] Urano R, Yoshimoto S, Hori K et al. Synergistic Protein-Protein and Protein-Lipid Interactions Drive SARS-CoV-2 Envelope Assembly. J Chem Inf Model. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42262910/

[12] McTiernan J, Zhang Y, Li S et al. Clustering of SARS-CoV-2 membrane proteins in lipid bilayer membranes. PLoS Comput Biol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42044155/

[13] Navhaya LT, Monama MZ, Matsebatlela TM et al. In-Depth Molecular Dynamics Simulations Reveal Ligand-Induced Modulations of the HSPA8-SARS-CoV-2 Spike Protein Interaction. Int J Mol Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42196270/

[14] Kongtaworn N, Sinsulpsiri S, Hanpaibool C et al. Molecular Dynamics and Solvated Interaction Energy Prioritize Cannabidiol and Cannabinol as Variant-Spanning SARS-CoV-2 RBD-ACE2 Interface Blockers. Molecules. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42075932/

[15] Cofas-Vargas LF, Olivos-Ramirez GE, Marrink SJ et al. A comparative nanomechanical study of antibody and nanobody binding to SARS-CoV-2 variants. Phys Chem Chem Phys. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41885290/

[16] Wang H, Li X, He P et al. Investigating the effects and underlying mechanisms of glycosylation sites on the immunogenicity of COVID-19 vaccines. Signal Transduct Target Ther. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42129141/

[17] Kumar A, Yadav AJ, Tripathi T et al. Glycan shielding and epitope reorganization drive sotrovimab resistance in SARS-CoV-2 Omicron variants. Arch Biochem Biophys. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42128042/

[18] Silva-Díaz A, Thépaut M, Ramírez-Cárdenas J et al. Enhancing lectin recognition via precise fluorination: Man(5) glycomimetics for targeting DC-SIGN. Bioorg Chem. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41856064/

[19] Chen M, Chen W, Jiang X et al. Virtual screening targeting the conserved domain of the IAV M2 protein reveals the potential broad-spectrum anti-IAV activity of ajmaline. Biochem Biophys Res Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41881854/

[20] Smatti MK, Al-Khatib H, Suleman M et al. Functional and structural characterization of the SARS-CoV-2 spike N481K mutation. Arch Virol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42243594/

[21] Altaf M, Kin Cheng MT, González-Vázquez LD et al. SARS-CoV-2 intra-host recombination promotes epistatic spike interactions and temperature-dependent adaptation. Cell Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42213788/

[22] Habeeb WH, Hanoush NH, Alani MT et al. Comparative Molecular Docking and Pharmacokinetic Profiling of Cinnamic Acid and Oleic Acid from Cinnamomum verum as Potential Inhibitors of Dengue Virus Proteins. Infect Dis Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42042315/

[23] Pravin MA, Khan MA, Singh SK. Identification of potent inhibitors targeting the pre-fusion DENV envelope protein: A consensus physics-and AI-based in silico multi-tier screening approach. Biochem Biophys Res Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42008872/

[24] Kori L, Chandra A, Mukhopadhyay L et al. E-protein variability in Zika virus strains: A possible new O-glycosylation site and its implications. Indian J Med Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42165713/

[25] Dubey A, Kumar M, Tufail A et al. Allophycocyanin inhibits HIV-1 gp120 and reverse transcriptase through enthalpy-driven binding and antioxidative protection: integrative computational and experimental insights. Sci Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41851190/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[26] Ait Lahcen N, Liman W, Zekri S et al. QSAR-Guided and Fragment-Based Drug Design of Monoterpenoid Inhibitors Targeting Ebola Virus Glycoprotein. Int J Mol Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41977174/

[27] Delgado-Maldonado T, Vargas-Salas G, Bandyopadhyay D et al. Ligand-Based Pharmacophore Modeling and Structure-Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS-CoV-2 Spike Protein-ACE2 Receptor Interaction. ChemMedChem. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42174382/

[28] Zhou X, Du H, Wang C et al. Identification of a Potential Dual-Target Candidate Against RSV F Protein and 15-LOX from TCMSP: Integrating Virtual Screening, Molecular Dynamics, and Experimental Evaluation. Int J Mol Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42074092/

[29] Sugumar M, Pragalath S, Kugarajah V. Immunoinformatics-based epitope prediction in MERS-CoV and docking analysis of Catharanthus roseus compounds for drug discovery. Comput Biol Chem. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42218862/

[30] Kobe N, Dreisewerd L, Lukšič M et al. In silico characterisation of a novel SARS-CoV-2 envelope protein inhibitor and in vitro validation against murine coronavirus. Bioorg Chem. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42119203/

[31] Alotaiq N, Dermawan D, Chtita S. Targeting Middle East Respiratory Syndrome Coronavirus Spike Fusion Machinery With Antiviral Peptides: In Silico Exploration of the Heptad Repeat 2 Domain. Microbiologyopen. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42082899/

[32] Dubey A, Kumar M, Tufail A. Suppressing viral assembly in human metapneumovirus by targeting fusion protein with natural compounds: a structural dynamics and energetics study. J Mol Model. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42043606/

[33] Salam DDA. In silico screening and molecular dynamics simulations of Epicatechin as an inhibitor of EBV LMP1. J Mol Graph Model. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41955735/

[34] Naveed M, Ali A, Aziz T et al. Identification of a novel multi epitope vaccine against human herpes virus 7 (HHV-7) to combat CNS disorders in children and adolescents using subtractive proteomics and immunoinformatic approaches. Hum Immunol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41905024/

[35] Ataya F, Alamro A, Alghamdi A et al. Identification of polyphenols as novel neuropilin-1 cendR pocket inhibitors to block SARS-CoV-2 entry and enhance variant resistance. PLoS One. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41871083/